Data from: Investigating the combined effects of jadomycin B and celecoxib against triple-negative breast cancer using zebrafish larval xenografts
Data files
Oct 24, 2025 version files 114.48 KB
-
HS337_A01_1A-187F.seq
1.25 KB
-
HS337_A02_1A-808R.seq
1.18 KB
-
HS337_A03_1B-187F.seq
1.32 KB
-
HS337_A04_1B-808R.seq
1.27 KB
-
HS337_A05_1C-187F.seq
1.28 KB
-
HS337_A06_1C-808R.seq
1.30 KB
-
HS337_A07_2A-183F.seq
1.26 KB
-
HS337_A08_2A-803R.seq
1.33 KB
-
HS337_A09_2B-183F.seq
1.30 KB
-
HS337_A10_2B-803R.seq
1.28 KB
-
HS337_A11_2C-183F.seq
1.30 KB
-
HS337_A12_2C-803R.seq
1.18 KB
-
HS337_B01_3G-187F.seq
1.30 KB
-
HS337_B02_3G-182R.seq
1.20 KB
-
HS337_B03_3R-187F.seq
1.31 KB
-
HS337_B04_3R-182R.seq
1.24 KB
-
HS337_B05_4G-804F.seq
1.20 KB
-
HS337_B06_4G-803R.seq
1.19 KB
-
HS337_B07_4R-804F.seq
1.21 KB
-
HS337_B08_4R-803R.seq
1.20 KB
-
raw_data_MTT.xlsx
29.31 KB
-
raw_injection_data_.xlsx
25.81 KB
-
raw_toxicity_data_.xlsx
27.64 KB
-
README.md
6.64 KB
Abstract
Breast cancer affects 1 in 8 Canadian women over their lifetime. Triple-negative breast cancer (TNBC) represents 10-20 % of all advanced stage breast cancers, often developing multi-drug resistance (MDR), commonly resulting in treatment failure. Jadomycin B (JB), a natural product of Streptomyces venezuelae, maintains cytotoxicity against MDR TNBCs, shown to be enhanced when combined with selective COX-2 inhibitor, celecoxib (CXB). Our objectives were to generate a fluorescent human TNBC cell line, as well as evaluate the toxicity and anticancer effect of JB combined with CXB using zebrafish larval xenografts. Fluorescent human TNBC MDA-MB-231 cells (231-EGFP) were generated and characterized for zebrafish larval xenografts. A maximum tolerated dose (MTD) in zebrafish larvae was determined for JB (20 mM) and CXB (5 mM). Zebrafish embryos were xenotransplanted with 231-EGFP cells and treated with the MTD of JB CXB. The combination of JB and CXB resulted in a 75% reduction in 231-EGFP fluorescence intensity, significantly higher than reductions caused by either drug alone (39% for JB, 15 % for CXB) (p < 0.05). This study demonstrates the safety and efficacy of JB combined with CXB in a zebrafish larval xenograft model for human TNBC, enhancing anticancer effects, similar to effects previously determined in vitro.
Hailey M. Stack, Michael G. Morash, Brendan T. McKeown, Lee D. Ellis, Kerry B. Goralski
Contact of Authors:
Hailey M. Stack
Department of Pharmacology, Faculty of Medicine, Dalhousie University
Halifax, NS, B3H 4R2
Kerry B. Goralski
College of Pharmacy, Faculty of Health, Department of Pharmacology
Halifax, NS B3H 4R2
Dataset DOI: 10.5061/dryad.3bk3j9kxp
Description of the data and file structure
raw_toxicity_data: excel file containing raw data collected from a phenotypic (fish embryo toxicity assay/FET) and a behavioural assay of various treatment groups (jadomycin B: 2.5-80 uM; celecoxib: 2.5-25 uM; combination treatment: jadomycin B (5-20 uM) + celecoxib (5-10 uM)). Phenotypic data is presented in percent survival (%) which was recorded every 24 hours over a 72 hour treatment. Phenotypic data is presented in difference in distance traveled during light-dark (mm) which was recorded during 30 mins of alternating light to dark transitions.
raw_data_MTT: excel file containing raw data collected from MTT metabolic activity assays of various treatments (jadomycin B (0.04-10 uM) + celecoxib (5uM) in MDA-MB-231-control, MDA-MB-231-mCherry, and MDA-MB-231-EGFP cell lines. 5 technical replicates (R1-5) and 3 biological replicates (Rep1-3) were preformed for each treatment in each cell line. Raw data is presented in absorbance values as well as a calculated percent viability (viability) and standard deviation (stdev).
raw_injection_data: excel file containing raw data collected from zebrafish embryos xenografts treated with jadomycin B (20uM) +/- celecoxib (5uM) at 0 hours and 72 hours post treatment. Data is presented as sum intensity (ROI Sum Intensity) calculated from fluorescent (GFP channel) microscope images take with a Nikon AZ100 Multizoom Microscope (set at 10X magnification and 4X objective) of xenografts in zebrafish embryos. Intensity fold change was calculated from dividing 72 hours post treatment by 0 hours post treatment (72h/0h) for each individual embryo. All intensity fold change was normalized to the average intensity fold change of the vehicle control to calculate precent reduction.
Sequencing Files: .seq files (containing sequencing reads) from Sanger Sequencing analysis of fluorescently transfected and control cell lines. The .seq files are plain text (fasta) file of the final base sequence from the sequencer.
List: HS337_A01_1A-187F.seq, HS337_A02_1A-808R.seq, HS337_A03_1B-187F.seq, HS337_A04_1B-808R.seq, HS337_A05_1C-187F.seq, HS337_A06_1C-808R.seq, HS337_A07_2A-183F.seq, HS337_A08_2A-803R.seq, HS337_A09_2B-183F.seq, HS337_A10_2B-803R.seq, HS337_A11_2C-183F.seq, HS337_A12_2C-803R.seq, HS337_B01_3G-187F.seq, HS337_B02_3G-182R.seq, HS337_B03_3R-187F.seq, HS337_B04_3R-182R.seq, HS337_B05_4G-804F.seq, HS337_B06_4G-803R.seq, HS337_B07_4R-804F.seq, HS337_B08_4R-803R.seq
Files and variables
File: raw_toxicity_data_.xlsx
Description: raw data collected from a phenotypic (fish embryo toxicity assay/FET) and a behavioural assay of various treatment groups (jadomycin B: 2.5-80 uM; celecoxib: 2.5-25 uM; combination treatment: jadomycin B (5-20 uM) + celecoxib (5-10 uM)). Phenotypic data was recorded manually from visual scoring and is presented in percent survival (%), which was recorded every 24 hours over a 72 hour treatment. Behavioural data was recorded using a Noldus Daniovision Behavioral Tracking instrument and is presented in difference in distance traveled during light-dark (mm) which was recorded during 30 mins of alternating light to dark transitions.
Any cells including "N/A" indicates a read that was excluded to phenotypic toxicity including major phenotypic toxicity/changes or death of the embryo.
File: raw_data_MTT.xlsx
Description: raw data collected from MTT metabolic activity assays of various treatments (jadomycin B (0.04-10 uM) + celecoxib (5uM) in MDA-MB-231-control, MDA-MB-231-mCherry, and MDA-MB-231-EGFP cell lines. 5 technical replicates (R1-5) and 3 biological replicates (Rep1-3) were preformed for each treatment in each cell line. Raw data is presented in absorbance values (measured at 550 nm using a BioTek Synergy HT plate reader Gen5 v2.01 software). Calculated percent viability (%viability) and standard deviation (stdev) is also presented in this data.
Cells including "N/A" for the Blank absorbance reading is due to only 3 blanks being used per plate compared to 5 technical replicates used for each treatment per plate.
File: raw_injection_data_.xlsx
Description: contains raw data collected from zebrafish embryos xenografts treated with jadomycin B (20uM) +/- celecoxib (5uM) at 0 hours and 72 hours post treatment. Data is presented as sum intensity (ROI Sum Intensity) calculated from fluorescent (GFP channel) microscope images take with a Nikon AZ100 Multizoom Microscope (set at 10X magnification and 4X objective) of xenografts in zebrafish embryos. Intensity fold change was calculated from dividing 72 hours post treatment by 0 hours post treatment (72h/0h) for each individual embryo. All intensity fold change was normalized to the average intensity fold change of the vehicle control to calculate precent reduction.
File: (HS337_A01_1A-187F.seq, HS337_A02_1A-808R.seq, HS337_A03_1B-187F.seq, HS337_A04_1B-808R.seq, HS337_A05_1C-187F.seq, HS337_A06_1C-808R.seq, HS337_A07_2A-183F.seq, HS337_A08_2A-803R.seq, HS337_A09_2B-183F.seq, HS337_A10_2B-803R.seq, HS337_A11_2C-183F.seq, HS337_A12_2C-803R.seq, HS337_B01_3G-187F.seq, HS337_B02_3G-182R.seq, HS337_B03_3R-187F.seq, HS337_B04_3R-182R.seq, HS337_B05_4G-804F.seq, HS337_B06_4G-803R.seq, HS337_B07_4R-804F.seq, HS337_B08_4R-803R.seq)
Description: All raw sequencing files (.seq) containing sequencing reads from Sanger Sequencing analysis of fluorescently transfected and control cell line to validate successful transfection.
For analysis in the publication, consensus amplicons were generated by aligning both forward and reverse strand sequencing reads (.seq files) as a megamer and exporting a consensus sequence using DNASTAR Laser gene core suite 12 analysis package (DNASTAR, USA). Sequences were aligned with the plasmid sequence (Addgene, Watertown, MA, USA), and the human genome sequence (GRCh38.p14 build, NCBI).